Umer Raffat

Pharma

Analysts to Gilead CEO: What's your plan to monetize remdesivir?

Just a day after remdesivir posted positive data, analysts hounded Gilead's CEO with one key question: When will the drug start making money?
Carly Helfand Apr 30, 2020 8:28pm

Allergan preparing to split after years of turmoil: analyst

Jun 19, 2019 10:50am

BMS-Celgene integration questions? Execs aren't answering

Apr 26, 2019 11:45am

'Old guard' generics players yield U.S. scripts lead

Apr 18, 2019 12:06pm

Already delayed in lung cancer, BMS pulls crucial Opdivo filing

Jan 24, 2019 12:24pm

Pfizer, Merck topped the Dow in 2018 despite biopharma declines

Jan 2, 2019 11:33am